News

April 25, 2017

SMA Community's Voice Heard “Loud and Clear” at Last Week's Patient Focused Drug Development Meeting with the FDA

SMA Community's Voice Heard “Loud and Clear” at Last Week's Patient Focused Drug Development Meeting with the FDA

On April 18, 2017, the SMA community—families, clinicians, researchers, industry and regulators—gathered for a Patient-Focused Drug Development (PFDD) Meeting with the FDA.

As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA), the FDA is required to...

READ MORE   |  

Topics: Community & Awareness, Our Impact, Advocacy, Front Page News

April 24, 2017

Biogen Releases New Data from Cherish and Nurture Trials

Biogen Releases New Data from Cherish and Nurture Trials

Biogen will present Phase 3 end of study SPINRAZA® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in children with later-onset (most likely to develop Type 2 or Type 3) spinal muscular atrophy...

READ MORE   |  

Topics: Clinical Trials, Front Page News

April 21, 2017

Cure SMA to Host Webinar on Spinraza Access, as List of Administration Sites is Released

Cure SMA to Host Webinar on Spinraza Access, as List of Administration Sites is Released

On Thursday, May 4, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA will hold a webinar updating the community on the status of Spinraza access. Among the topics covered will be:

  • The current status of dosing in states across the US
  • Administration sites,...

READ MORE   |  

Topics: Community & Awareness, Front Page News

Items 1 - 3 of 281  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software